Q-omics provides the consensus-scored RNF26 profile across patient tissues and cancer cell-line models. RNF26 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNF26 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RNF26 RNA expression shows 19,009 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where RNF26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF26 survival associations across molecular data types. RNF26 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF26 RNA expression–survival associations across cancer types. High RNF26 expression shows unfavorable associations in MESO, BLCA, ACC, LIHC, PAAD and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNF26 RNA expression.
This table summarizes RNF26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF26 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRP, LIHC, LUSC and LUAD. The HNSC box plot shows higher RNF26 RNA expression in tumor versus normal tissue (log2 FC = +1.001, t-test p < 0.001).
This table shows molecular features associated with RNF26 in patient tissues and cancer cell lines. In patient samples, RNF26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
